Table 2.
Pharmacokinetic parameters of LO and laninamivira
| Drug | Sample type | BAL fluid | Cmax (μg/ml) | Tmax (h) | AUClast (μg·h/ml) | t1/2 (h) |
|---|---|---|---|---|---|---|
| LO | Plasma | 0.162 (0.013) | 0.3 | 0.705 (0.045) | 2.6 | |
| ELF | BAL1 | 102.40 (94.3) | 4.0 | 716.5 (393.8) | 41.7 | |
| ELF | BAL2 | 7.25 (4.62) | 4.0 | 87.7 (24.3) | 41.3 | |
| AM | BAL1 | 2,085 (325) | 8.0 | 71,719 (13,585) | 69.5 | |
| AM | BAL2 | 1,088 (364) | 8.0 | 31,942 (7,060) | 89.9 | |
| Laninamivir | Plasma | 0.025 (0.001) | 3.5 | 0.826 (0.041) | 45.7 | |
| ELF | BAL1 | 8.57 (6.94) | 4.0 | 222.9 (42.7) | 141 | |
| ELF | BAL2 | 2.40 (1.67) | 4.0 | 69.4 (11.5) | 241 | |
| AM | BAL1 | 125.1 (25.2) | 8.0 | 17,271 (4,824) | 1029 | |
| AM | BAL2 | 152.3 (48.0) | 8.0 | 10,325 (1,715) | 142 |
a
Pharmacokinetic parameters were estimated using the sparse sampling option in WinNonlin and are presented as means (SE) for Cmax and AUClast.